13/09/2017 22:27:41

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

Related content
31 Dec - 
Veloxis Announces the Total Number of Shares and Voting..
29 Dec - 
Veloxis Pharmaceuticals Announces Financial Calendar fo..
22 Dec - 
Veloxis Pharmaceuticals A/S Grants Warrants Under Exist..
Related debate
19 Jan - 
Baunsgård og msn. Tja, vi kan gætte herfra og til månen..
19 Jan - 
Jeg tror at sandsyneligheden stiger for en overtagelse ..
17 Jan - 
Hvis man kigger lidt nærmere på deres forskning, så ska..

Company Release no. 19/2017

   

To: NASDAQ Copenhagen A/S                                     Copenhagen, Denmark, 13 September 2017

   

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

 

Veloxis Pharmaceuticals A/S is pleased to announce that Veloxis Pharmaceuticals, Inc. has hired Ulf Meier-Kriesche, MD, to serve as its Chief Scientific Officer.  In this role, Dr. Meier-Kriesche will oversee the Company’s regulatory and medical affairs departments.

Dr. Meier-Kriesche is a board certified Nephrologist with over 20 years of practical clinical experience in transplantation.  He is the author of over 170 scientific publications that have appeared in numerous peer-reviewed journals.  Additionally, Dr. Meier-Kriesche served on the faculty of the University of Florida Medical School from 2001 until 2011.   

Prior to joining Veloxis, Dr. Meier-Kriesche was the Clinical Trials Lead Immunology at Bristol-Myers Squibb.  Dr. Meier-Kriesche has also worked for Astellas Pharma.    

Craig Collard, CEO of Veloxis Pharmaceuticals A/S said “Veloxis is committed to serving the needs of the transplant community and the appointment of Ulf Meier-Kriesche further solidifies that commitment.  Ulf’s background and experience as a transplant nephrologist will help Veloxis be more responsive to the concerns of clinicians and ultimately better support the transplant community.”

Ulf Meier-Kriesche commented “I am thrilled to join Veloxis because of the wonderful opportunity we have together to bring new therapeutic options to transplant patients.”

 

For more information, please contact:

Craig A. Collard            

President & CEO                      

Phone: +1 919 591 3090                     

Email: cac@veloxis.com                      

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  

For further information, please visit www.veloxis.com.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Jan
VELO
https://clinicaltrials.gov/ct2/show/NCT03386305?term=Envarsus&recrs=ab&cond=Liver&draw=2&rank=13
8
19 Jan
VELO
Baunsgård og msn. Tja, vi kan gætte herfra og til månen omkring overtagelse, bagtanker fra de to sto..
4
16 Jan
VELO
  Kina har generelt gjort det meget lettere for internationale selskaber, at få nye innovative lægem..
4
17 Jan
VELO
Kan se linket ikke fører direkte ind på Veloxis, så den skal I selv lige søge på. Men tydeligt at se..
2
17 Jan
VELO
Skal først og fremmest sige, at min investering i Veloxis alene er ud fra en forventning om, at nuvæ..
2
15 Jan
VELO
Hvis du hører CC fra 3. Kvartal, så hører du det. Husk på at de første 30 dages behandling er gr..
2
15 Jan
VELO
Mange tak, af en eller anden grund var jeg ikke stødt på siden før.  Ellers venter jeg som i andre p..
2
16 Jan
VELO
Tak, Og så kan man måske forstille sig, at Veloxis får deres tilgodehavende fra Chiesi m.fl., når  m..
1
15 Jan
VELO
Det var kun en meget kortvarig stigning de kunne bidrage med i dag. Der skal ikke mange køb/salg til..
1
15 Jan
VELO
Det er jo så din subjektive vurdering ;)
1

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

19/01/2018 15:28:15
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Invesco Ltd. : Form 8.3 - Informa Plc

Related news
19/01/2018 13:58:51
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Invesco Ltd. (b) Owner or control..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

19/01/2018 10:18:53
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Vera Bradley Annual Outlet Sale Tickets Available January 22, 2018
2
Gala Pharmaceuticals Sees 2018 as Breakthrough Year for Company
3
Aluminum Association Responds to Submission of Section 232 Report to the President

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 January 2018 00:00:04
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180112.1 - EUROWEB7 - 2018-01-22 01:00:04 - 2018-01-22 00:00:04 - 1000 - Website: OKAY